Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2007-12-25
2007-12-25
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
Reexamination Certificate
active
10407864
ABSTRACT:
This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions.
REFERENCES:
patent: 4186183 (1980-01-01), Steck et al.
patent: 4217344 (1980-08-01), Vanlerberghe et al.
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4261975 (1981-04-01), Fullerton et al.
patent: 4485054 (1984-11-01), Mezei et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4603044 (1986-07-01), Geho et al.
patent: 4737323 (1988-04-01), Martin et al.
patent: 4774085 (1988-09-01), Fidler
patent: 4837028 (1989-06-01), Allen
patent: 4885172 (1989-12-01), Bally et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 4952408 (1990-08-01), Rahman
patent: 4957773 (1990-09-01), Spencer et al.
patent: 5023087 (1991-06-01), Yau-Young
patent: 5059421 (1991-10-01), Loughrey et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5165922 (1992-11-01), Hellstrom et al.
patent: 5171578 (1992-12-01), Bally et al.
patent: 5534499 (1996-07-01), Ansell
patent: 5543152 (1996-08-01), Webb et al.
patent: 5552156 (1996-09-01), Burke
patent: 5567592 (1996-10-01), Benet et al.
patent: 5595756 (1997-01-01), Bally et al.
patent: 5714163 (1998-02-01), Forssen et al.
patent: 5736155 (1998-04-01), Bally et al.
patent: 5741516 (1998-04-01), Webb et al.
patent: 5755788 (1998-05-01), Strauss
patent: 5785987 (1998-07-01), Hope et al.
patent: 5814335 (1998-09-01), Webb et al.
patent: 5820873 (1998-10-01), Choi et al.
patent: 5837282 (1998-11-01), Fenske et al.
patent: 5885613 (1999-03-01), Holland et al.
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 6056973 (2000-05-01), Allen et al.
patent: 6110491 (2000-08-01), Kirpotin
patent: 6320017 (2001-11-01), Ansell
patent: 6355268 (2002-03-01), Slater et al.
patent: 6471943 (2002-10-01), Placke et al.
patent: 6566395 (2003-05-01), Moran
patent: 6723338 (2004-04-01), Sarris et al.
patent: 2003/0147945 (2003-08-01), Tardi et al.
patent: WO 91/17424 (1991-11-01), None
patent: WO 95/08986 (1995-04-01), None
patent: WO 98/17256 (1998-04-01), None
patent: WO 99/13816 (1999-03-01), None
patent: WO 99/51202 (1999-10-01), None
patent: WO 00/23052 (2000-04-01), None
U.S. Appl. No. 08/316,394 entitled “Glycosylated Protein-Liposome Conjugates and Methods for their Preparation,” filed Sep. 30, 1994.
U.S. Appl. No. 08/316,407 entitled “Bilayer Stabilizing Components and their use in Forming Programmable Fusogenic Liposomes,” filed Sep. 30, 1994.
U.S. Appl. No. 08/996,783 entitled “Polyamide Oligomers,” filed Feb. 2, 1998.
Bloomfield, V., “Quasi-Elastic Light Scattering Application in Biochemistry and Biology,”Ann. Rev. Biophys. Bioeng. 10:421-450, 1981.
Burris, H. et al., “Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units in Vitro,”J. Natl. Cancer Inst. 84(23):1816-1825, Dec. 1992.
Chu, E. et al.,Physician's Cancer Chemotherapy Drug Manual 2002, Jones and Bartlett Publishers, Sudbury, Massachusetts, 2002.
Clements, M. et al., “Antiangiogenic Potential of Camptothecin and Topotecan,”Cancer Chemother. Pharmacol. 44:411-416, 1999.
Corbett, T. et al.,Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Humana Press Inc., Totowa NJ, 1997, Ch. 5, “In Vivo Methods for Screening and Preclinical Testing” pp. 75-99.
Deamer, D. et al., “Larger Volume Liposomes by an Ether Vaporization Method,”Biochim. et Biophys. Acta 443:629-634, 1976.
Dumontet, C. et al., “Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death,”J. Clin. Oncol. 17(3):1061-1070, Mar. 1999.
Emerson, D. et al., “In Vivo Antitumor Activity of Two New Seven-Substituted Water-Soluble Camptothecin Analogues,”Cancer Res. 55:603-609, Feb. 1995.
Erickson-Miller, C. et al., “Differential Toxicity of Camptothecin, Topotecan and 9-Aminocamptothecin to Human, Canine, and Murine Myeloid Progenitors (CFU-GM) in Vitro,”Cancer Chemother. Pharmacol. 39:467-472, 1997.
Fenske, D. et al., “Ionophore-Mediated Uptake of CiproFloxacin and Vincristine into Large Unilamellar Vesicles Exhibiting Transmembrane Ion Gradients,”Biochim. et Biophys. Acta 1414:188-204, 1998.
Fraley, R. et al., “Entrapment of a Bacterial Plasmid in Phospholipid Vesicles: Potential for Gene Transfer,”Proc. Natl. Acad. Sci. USA 76(7):3348-3352, Jul. 1979.
Grochow, L. et al., “Pharmacokinetics and Pharmacodynamics of Topotecan in Patients with Advanced Cancer,”Drug Metabolism and Disposition 20(5):706-713, 1992.
Gruner, S.,Liposomes—from Biophysics to Therapeutics, Marcel Dekker, Inc., New York, Ch. 1, “Materials Properties of Liposomal Bilayers,” pp. 1-38.
Hardman, W. et al., “Efficacy of Treatment of Colon, Lung and Breast Human Carcinoma Xenografts with: Doxorubicin, Cisplatin, Irinotecan or Topotecan,”Anticancer Research 19:2269-2274, 1999.
Heath, T., “Covalent Attachment of Proteins to Liposomes,”Methods in Enzymology 149:111-119, 1987.
Hope, M. et al., “Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure. Characterization of Size Distribution, Trapped Volume and Ability to Maintaine a Membrane Potential,”Biochim. et Biophys. Acta 812:55-65, 1985.
Hsiang, Y-H, et al., “Identification of Mammalian DNA Topoisomerase I as an Anticellular Target of the Anticancer Drug Camptothecin,”Cancer Research 48:1722-1726, Apr. 1988.
Hudson, W. et al., “Xenotransplantation of Human Lymphoid Malignancies is Optimized in Mice with Multiple Immunologic Defects,”Leukemia 12:2029-2033, 1998.
Kluin-Nelemans, H. et al., “A New Non-Hodgkin's B-Cell Line (DoHH2) with a Chromosomal Translocation t(14;18) (q32;q21),”Leukemia 5(3):221-224, Mar. 1991.
King, R.E.,Remington's Pharmaceutical Sciences, 17thEd., Mack Publishing Co., Philadelphia, PA, 1985, Part 8, “Pharmaceutical Preparations and Their Manufacture,” pp. 1409-1677.
Leonetti, J-P. et al., “Antibody-Targeted Liposomes Containing Oligodeoxyribonucleotides Complementary to Viral RNA Selectively Inhibit Viral Replication,”Proc. Natl. Acad. Sci. USA 87:2448-2451, Apr. 1990.
Madden, T. et al., “The Accumulation of Drugs within Large Unilamellar Vesicles Exhibiting a Proton Gradient: A Survey,”Chem. and Phys. of Lipids 53:37-46, 1990.
Mayer, L. et al., “Characterization of Liposomal Systems Containing Doxorubicin Entrapped in Response to pH Gradients,”Biochim. et Biophys. Acta 1025:143-151, 1990.
Mayer, L. et al., “Techniques for Encapsulating Bioactive Agents into Liposomes,”Chem. and Phys. of Lipids 40:333-345, 1986.
Mayer, L. et al., “Vesicles of Variable Sizes Produced by a Rapid Extrusion Procedure,”Biochim. et Biophys. Acta 858:161-168, 1986.
McCabe, F. et al., “Comparative Activity of Oral and Parenteral Topotecan in Murine Tumor Models: Efficacy of Oral Topotecan,”Cancer Investigation 12(3):308-313, 1994.
Merck Index, 11thed. 1989, Entry Nos. 9887, 9891, & 9893.
O'Leary, J. et al., “Antiangiogenic Effect of Camptothecin Analogues 9-Amino-20(S)-Campthothecin, Topotecan, and CPT-11 Studied in the Mouse Cornea Model,”Clinical Cancer Research 5:181-187, Jan. 1999.
Ormrod, D. et al., “TOPOTECAN—A Review if its Efficacy in Small Cell Lung Cancer,”Drugs 58(3):533-551, Sep. 1999.
Plowman, J. et al.,Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Humana Press Inc., Totowa NJ, 1997, Ch. 6, “Human Tumor Xenograft Models in NCI Drug Development,” pp. 101-125.
Renneisen, K. et al., “Inhibition of Expression of Human Immunodeficiency Virus-1 in Vitro by Antibody-Targeted Liposomes Containing Antisense RNA to theenvRegion,”J
Ahkong Quet F
Burge Clive T R
Cabanillas Fernando
Goldie James H
Klimuk Sandra K
Hana Biosciences, Inc.
Kishore Gollamudi S.
Seed Intellectual Property Law Group PLLC
LandOfFree
Compositions and methods for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873796